Overview

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients who complete study B2601001 may participate in this trial and receive AAB-003 (PF-05236812). Each patient's participation will last approximately 52 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Collaborator:

JANSSEN Alzheimer Immunotherapy Research & Development, LLC